Introduction:
In March 2025, the National Healthcare Security Administration (NHSA) of China uniformly introduced new pricing items for implantable “artificial hearts” and engaged in discussions with manufacturers to reduce product prices. Aerospace Taixin Technology Co., Ltd. took the lead by lowering the price to ¥499,000 per unit (approximately $69,000 USD), bringing the overall treatment cost down to ¥700,000 (approximately $97,000 USD). The reimbursement policies for Ventricular Assist Devices (VADs) are also gradually improving, offering a ray of hope to end-stage heart failure patients who have been awaiting heart donors.
1. VADs: The Ultimate Solution for End-Stage Heart Failure Patients
Heart failure is often referred to as the “cancer” of cardiovascular diseases. Historically, heart transplantation was virtually the only option for end-stage heart failure patients. In 2023, according to HQMS data, there were over 14 million hospitalizations for heart failure in China, accounting for 18% of all cardiovascular disease hospitalizations. Among these, individuals aged 65 and above comprised 74%, highlighting how an aging population exacerbates the burden of heart failure. Currently, end-stage heart failure patients represent 5–10% of hospitalized heart failure cases. Amidst a shortage of heart donors, implantable Ventricular Assist Devices (VADs) have emerged as a significant alternative.
Patients with end-stage heart failure (NYHA Class III–IV) are the primary candidates for VADs, facing a five-year mortality rate as high as 80%, surpassing that of breast cancer (21%) and colon cancer (35%). According to the “2023 Expert Consensus on Preoperative Evaluation and Management of Left Ventricular Assist Device Candidates in China,” clinical decisions regarding VADs must strictly align with the following scenarios:
- Bridge to Transplantation (BTT), Bridge to Candidacy (BTC), or Bridge to Recovery (BTR): These account for 60% of global VAD implantations, with an average support duration of 12–18 months.
- Destination Therapy (DT): Applicable to 40% of patients ineligible for transplantation, requiring lifelong device support, with a five-year survival rate of 58% (INTERMACS data).
Patients exhibiting the following preoperative conditions have a significantly lower risk-benefit ratio for VAD implantation:
- Severe Right Heart Failure: Post-LVAD implantation, the incidence of right heart failure is approximately 20%.
- End-Organ Failure: Patients with an estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m² experience doubled postoperative mortality rates.
Additionally, psychosocial factors significantly impact surgical outcomes. U.S. studies indicate that patients lacking family support have a postoperative one-year non-compliance failure rate exceeding 30%.
2. Global Regulatory Landscape: FDA and NMPA’s Product Race
Currently, Abbott dominates the global VAD market. Its HeartMate 3 is the only implantable left ventricular assist system globally certified by the National Medical Products Administration (NMPA) of China, the European Union’s CE, and the U.S. FDA, with over 36,000 implants worldwide. In April 2024, HeartMate 3 achieved registration and market entry in China.
In 2019, EVAHEART by Yongrenxin became the first VAD product registered and marketed in China. To date, there are five implantable VAD products from four domestic manufacturers available in the country. While domestic VADs have achieved coverage across three generations of technology, breakthroughs are still needed in bearing lifespan and intelligent control algorithms.
3. The Technological Debate: Magnetic vs. Hydraulic Suspension
- Magnetic Suspension Technology (Representative Product: HeartMate 3):
- Advantages: Low shear force (<5 Pa), low hemolysis (plasma free hemoglobin <10 mg/dL).
- Disadvantages: Risk of thrombosis in secondary flow paths (HeartMate 3 has a 10% stroke rate two years post-operation).
- Clinical Data: Five-year survival rate post-HeartMate 3 implantation is approximately 77%, nearly equivalent to heart transplantation.
- Innovations: In 2023, Abbott introduced an adaptive flow regulation algorithm that dynamically adjusts pump speed based on physical activity.
- Hydraulic Suspension Technology (Representative Product: EVAHEART):
- Advantages: Biomimetic pulsatile blood flow (pulse pressure difference of 20–30 mmHg), no secondary flow path design.
- Disadvantages: Larger size and weight (requires open-chest implantation), higher power consumption (5W vs. 3W for magnetic suspension).
- Clinical Data: The EVA-Pulsar is currently undergoing a head-to-head COMPETENCE clinical trial against HeartMate 3 in the U.S. Early results show no significant differences in survival rates and heart failure recovery, but EVA-Pulsar has a 100% stroke-free survival rate at 90 days, notably higher than HeartMate 3.
- Hybrid Magnetic-Hydraulic Technology (Representative Product: HeartCon):
- Positioning: Cost-effective approach, with surgical costs expected to be under ¥500,000 (approximately $69,000 USD).
- Risks: Insufficient rotor balance stability.
4. Clinical Application Status: Surgical Volume, Techniques, and Physician Proficiency Gaps
- Global Surgical Volume Distribution:
- United States: In 2022, there were 4,120 LVAD implantations, with DT accounting for 58%.
- Europe: Approximately 1,500 annual implantations, with 70% concentrated in Germany and the UK.
- China: According to data from the National Health Commission’s quality control, from 2017 to the end of 2023, 132 hospitals nationwide performed 908 LVAD implantations, with annual numbers increasing. Data from the 2025 Tongji International Cardiovascular Conference (TICC) revealed that in 2024, Chinese hospitals conducted 779 LVAD implantations, a year-on-year increase exceeding 100%.
- Surgical Technique Evolution:
- Traditional Approach: Median sternotomy with cardiopulmonary bypass assistance.
- Minimally Invasive: In 2024, Yongrenxin performed the first left thoracotomy implantation, reducing surgery time to three hours.
- Complication Management: Percutaneous cable infection rates remain at 15%; Abbott’s new generation percutaneous cables with antibacterial coatings have reduced this to 8%.
- Physician Proficiency Bottleneck:
U.S. data indicates that experienced cardiac surgeons need to perform 50 LVAD surgeries to reduce mortality rates from 22% to 7%. In China, LVAD surgeries are primarily concentrated in a few major centers. In 2023, only 23 hospitals (17%) performed more than 10 VAD implantations, accounting for 627 cases (70% of total implantations). Even in China’s top teaching hospitals, LVAD technology is still in the exploratory stage, far from standardization and widespread adoption.
5. Payment Systems: Breaking the Financial Barrier of Sky-High Costs
- Cost Analysis:
Currently, the average perioperative cost for LVAD surgery in China exceeds ¥1 million (approximately $139,000 USD), including ¥500,000–¥1,000,000 (approximately $69,000–$139,000 USD) for domestic VAD devices, approximately ¥1.5 million (approximately $208,000 USD) for Abbott’s HeartMate 3, and ¥300,000–¥500,000 (approximately $42,000–$69,000 USD) for examinations, surgery, and hospitalization. This does not account for long-term anticoagulant medication and battery or consumable replacements, making it an exorbitant medical expense for most Chinese patients. - Insurance Breakthroughs:
- June 2022: Guangdong Provincial Healthcare Security Administration included “cardiac assist devices” as cardiac surgery materials in the “Guangdong Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Medical Consumables Catalog (2022),” allowing reimbursement through medical insurance funds.
- 2024: Wuxi’s employee medical insurance reimbursement catalog included “artificial hearts,” with patients bearing only about 20% of the cost.
- September 2024: Beijing’s Healthcare Security Administration approved four hospitals—Anzhen Hospital, Fuwai Hospital, Chaoyang Hospital, and Peking University Third Hospital—to perform “artificial heart” implantation surgeries eligible for medical insurance reimbursement. Implantable ventricular assist pump installation and catheter fixation devices were included in Beijing’s Class A medical insurance reimbursement.
- March 2025: The NHSA issued the “Cardiovascular System Medical Service Price Project Establishment Guide (Trial),” uniformly adding “ventricular assist device implantation fee,” “ventricular assist device removal fee,” and “cardiac implantable device adaptation fee” nationwide. This policy addresses the pricing issues for artificial heart implantation, removal, and postoperative adjustments. The project has been implemented in Beijing, Tianjin, and Ningxia. On April 1, Tianjin’s Healthcare Security Administration took the lead in setting government-guided prices, specifying an implantation fee of ¥13,000 (approximately $1,800 USD) and a removal fee of ¥6,500 (approximately $900 USD). Subsequently, the NHSA engaged with Aerospace Taixin, Shenzhen Core Medical, Chongqing Yongrenxin, Suzhou Tongxin Medical, and Abbott to guide companies in appropriately reducing the terminal online prices of “artificial hearts.” Aerospace Taixin committed to a ¥100,000 (approximately $14,000 USD) price reduction to ¥499,000 per unit (approximately $69,000 USD). Consequently, including hospitalization and medication costs, the total cost of an artificial heart implantation surgery decreased from over ¥1 million to ¥700,000 (approximately $97,000 USD).
6. Future Outlook: From “Heart Replacement” to “Heart Enhancement” (continued)
Pediatric Adaptation: Core Medical’s CorHeart 6 has been used successfully in children weighing 12 kilograms, breaking the 20-kilogram weight limitation of imported devices.
Domestic Substitution Strategies:
Cost Advantage: Aerospace Taixin has utilized aerospace-grade titanium alloy precision casting technology to reduce pump body costs by 60%.
Export Strategy: Yongrenxin’s EVAHEART received CE certification from the European Union and entered the Southeast Asian market in 2024.
Ecosystem Construction: Tongxin Medical collaborated with MicroPort Robotics to develop VAD surgical assistance systems, lowering the learning curve for surgeons.
Conclusion:
The ultimate goal of artificial hearts is not to replace the human heart but to rebuild hope for life in an era of organ shortages. When the price of domestically produced VADs falls to ¥300,000 (approximately $42,000 USD), when wireless charging technology frees patients from external cables, and when AI systems regulate blood flow more precisely than humans can — this collaboration between medicine and engineering is redefining what is possible for human life.
[Disclaimer]: The above content reflects analysis of publicly available information, expert insights, and BCC research. It does not constitute investment advice. BCC is not responsible for any losses resulting from reliance on the views expressed herein. Investors should exercise caution.